Coronavirus – COVID-19 – Potential Treatment Methods

Mar 19, 2020

  • From what I understand, they had 24 patients that were included in the study and given hydroxychloroquine, 600mg once daily. They compared with patients in two other towns that were not part of the study and therefore not given the medication. Unclear on matching. By day 6, only 25% of the patients in the chloroquine group were positive compared to 90% in the control group. A surprising finding was that patients that were also given Azithromycin to prevent or treat bacterial superinfection had even better results on Chloroquine.
  • Was just on television discussing HCQ, first well controlled study against COVID-19. 600 mg HCQ per day after 6 days, 90% of patients tested COVID-19 negative.  96% of control group tested positive after 6 days.
  • Details on the Chinese treatment plans can be found in English through
  • we’re using triple therapy ( off -lablel) for documented cases admitted to ICU: Hydrocy chloroquine/ choloquine phosphate twice daily for 5 days + Tamiflu bid for 5 days + kaletra 2 (200/50) bid for 5 days extended to 14 days if needed
  • If available, cocktail of RNA synthase inhibitor Remdesivir+ JAK inhibitor Bacritinib + IL6 inhibitor Tocilizumab should be the combo to try in ICU pts.
  • Soliris (Eculizumab) will be used to modulate the activity of the distal complement preventing the formation of the membrane attack complex. By modulating this portion of the immune response, mortality can be halted while the patient has time to recover from the virus with supportive medical care.
  • Off label Tocilizumab asap. Most hospital carries it, may calm down the cytokine storm. Chinese are using it
  • Please read this paper. ARB+Statin can lower 50% mortality of virus pneumonia. This combination was used in treating Ebola. It was effective.
  • Experts on ACE2 are of the opinion that ARBs (+Statins) would be highly protective vs. #COVIDー19
  • Chloroquine  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro  following the in vitro results, 20 clinical studies were launched in several Chinese hospitals. The first results obtained from more than 100 patients showed the superiority of chloroquine compared with treatment of the control group in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance



Recent Categories

View All